Pfizer Oncology: Who We Are and What We Do

One way or another, cancer touches all of our lives. That is why nothing is more personal, or more urgent, than our goal to find cures for these deadly diseases.

OUR IMPACT

- **23** innovative cancer medicines and biosimilars, treating 30 types of cancer.
- **11** FDA Breakthrough Therapy Designations since 2013.
- **up to 12** potential approvals expected before the end of 2025.

OUR SCIENCE

- **130** ongoing clinical trials with a Pfizer oncology medicine.
- **8,500+** active participants in ongoing Pfizer-sponsored oncology clinical trials.

Innovative Modalities to Drive Potential Future Therapies

- **Monoclonal Antibodies (mAbs)**
  Act like human antibodies in the immune system to target cancer cells.

- **Bispecifics**
  Bring cancer and immune cells together, causing an immune response that attacks the cancer.

- **Antibody-drug Conjugates (ADCs)**
  Deliver chemotherapy or a radioactive particle directly to cancer cells.

- **Cancer Vaccines**
  Introduce antigens that trigger an immune response.

- **Small Molecules**
  Pass through cell membranes to reach targets within cancer cells.

OUR AREAS OF FOCUS

- **Breast Cancer**
  Revolutionizing standards of care across multiple subtypes and stages.

- **Genitourinary Cancer**
  Leveraging a 15-year legacy to advance treatment for pervasive and hard-to-treat cancers.

- **Colorectal Cancer**
  Targeting the aggressive biology of BRAF + metastatic colorectal cancer.

- **Blood Cancer**
  Changing the treatment landscape for rare, life-threatening cancers.

- **Lung Cancer**
  Advancing biomarker-driven therapies for the leading cause of cancer-related death.

- **Melanoma**
  Delivering a precision medicine for mutation-driven, advanced melanoma.

- **Biosimilars**
  Improving patient access to essential medicines.

We’ve made meaningful progress – but our work is far from finished. Millions of people are living with cancer, and millions more will receive a diagnosis in the future. They are the reason we will continue to work tirelessly to deliver on our purpose:

**BREAKTHROUGHS THAT CHANGE PATIENTS’ LIVES.™**

Intended for use with media professionals only. This document includes forward-looking statements that are subject to substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Additional information can be found in Pfizer’s filings with the U.S. Securities and Exchange Commission, including Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2019 and subsequent reports on Form 10-Q, which are available at www.sec.gov and www pfizer.com.

© Pfizer Inc. All rights reserved. June 2020.